Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Despite significant improvements in diagnosis and therapy over the past 20 years, breast cancer remains a worldwide public health issue. In particular, triple negative breast cancer (TNBC), a subset of very aggressive breast tumors, is associated with a poor prognosis and has very few efficient therapeutic options. The ectonucleotidase CD73 has recently emerged as a promising new target for TNBC in preclinical models. Pharmacological targeting of CD73 and downstream adenosine A2A/A2B receptor signaling is currently an active field of research that could lead to the development of new cancer therapeutics, including options against TNBC. AREAS COVERED: This article reviews the basic structural and molecular features of CD73 and its role in the development of cancer, with a particular focus on CD73's role in the biology of TNBC. EXPERT OPINION: It was recently demonstrated that CD73 expression in TNBC is associated with worse clinical outcomes and increased resistance to anthracycline chemotherapy. Targeted blockade of the CD73/A2A axis has been shown to impair various aspects of tumorigenesis and displays synergism with other anti-cancer treatments in preclinical studies. Hence, we strongly argue for the development of CD73 inhibitors and for the repositioning of A2A antagonists in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585
Immunity, inflammation and cancer: a leading role for adenosine
Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3613 · Cited by 765
Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003884 · Cited by 540 · cited 1×
“Last but not the least, CD73 and its ATP-hydrolyzing partner CD39 have recently been shown to be expressed at the surface of exosomes released by several cancer cell lines or present in pleural effusions of mesothelioma patients [117].”
BackgroundHuang, S., Apasov, S., Koshiba, M., & Sitkovsky, M. (1997) · Blood · doi:10.1182/blood.v90.4.1600 · Cited by 531
Coordinated Adenine Nucleotide Phosphohydrolysis and Nucleoside Signaling in Posthypoxic Endothelium
Eltzschig, H. K., Ibla, J. C., Furuta, G. T., Leonard, M. O., Jacobson, K. A., Enjyoji, K., Robson, S. C., & Colgan, S. P. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030891 · Cited by 499 · cited 1×
“Of note, several other components of the adenosinergic pathway, such as A2A, A2B and CD39, are upregulated by hypoxia [109], whereas AK and equilibrative adenosine transporters are transcriptionally silenced by hypoxia [59,60,110].”
BackgroundThe pre-metastatic niche: finding common ground
Sceneay, J., Smyth, M. J., & Möller, A. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9420-1 · Cited by 422 · cited 1×
“These very interesting findings suggest that tumor cells releasing CD73/CD39-equipped exosomes could remotely impair tumor immunosurveillance and thus favor the formation of premetastatic niches in secondary organs [118].”
BackgroundSitkovsky, M. V., Kjaergaard, J., Lukashev, D., & Ohta, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0229 · Cited by 253 · cited 1×
“This connexion between hypoxia and the adenosinergic system creates a powerful pro-tumorigenic loop where the hypoxic tumor microenvironment drives the accumulation of extracellular adenosine and the adenosine receptor-mediated tumor immune evasion [114,115].”
BackgroundGaravaglia, S., Bruzzone, S., Cassani, C., Canella, L., Allegrone, G., Sturla, L., Mannino, E., Millo, E., De Flora, A., & Rizzi, M. (2012) · Biochemical Journal · doi:10.1042/bj20111263 · Cited by 94 · cited 2×
“3 Tridimensional structure Until recently, the tridimensional structure of human CD73 could only be modelized in silico using structures of several bacterial 5¢-nucleotidases that have been resolved previously [47-50].”
Background
Cited by
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Self-citationPurinergic regulation of the immune system
Cekic, C., & Linden, J. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.4 · Cited by 787
CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer
Turcotte, M., Spring, K., Pommey, S., Chouinard, G., Cousineau, I., George, J., Chen, G. M., Gendoo, D. M. A., Haibe-Kains, B., Karn, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3569 · Cited by 257
Self-citationGuestini, F., McNamara, K. M., Ishida, T., & Sasano, H. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1125469 · Cited by 58
“[100] The generation of adenosine by the ectonucleotidase CD73 played an important role in tumor immunoescape, since adenosine activates receptors upstream shutter release of a cascade of signaling pathways involving mitogen-activated protein kinase, protein kinase C, cAMP-dependent protein kinase and PI3K/Akt/mTOR,[1…”
BackgroundInfluential
Metadata
- Authors
- Allard, B., Turcotte, M., & Stagg, J.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2014-05-06
- Volume
- 18
- Issue
- 8
- Pages
- 863-881
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2120485507
- Cited by
- 46
- References
- 9
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. https://app.cochat.ai/papers/10.1517/14728222.2014.915315
- The paper
- Allard, B., Turcotte, M., & Stagg, J. (2014). Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.2014.915315
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.